Ibrutinib Plus Venetoclax for First-Line Treatment of Chronic Lymphocytic Leukemia: Primary Analysis Results From the Minimal Residual Disease Cohort of the Randomized Phase II CAPTIVATE Study
Articolo
Data di Pubblicazione:
2021
Abstract:
CAPTIVATE (NCT02910583), a randomized phase II study, evaluates minimal residual disease (MRD)-guided treatment discontinuation following completion of first-line ibrutinib plus venetoclax treatment in patients with chronic lymphocytic leukemia (CLL).
Tipologia CRIS:
1.1 Articolo in rivista
Elenco autori:
Wierda, William G; Allan, John N; Siddiqi, Tanya; Kipps, Thomas J; Opat, Stephen; Tedeschi, Alessandra; Badoux, Xavier C; Kuss, Bryone J; Jackson, Sharon; Moreno, Carol; Jacobs, Ryan; Pagel, John M; Flinn, Ian; Pak, Yvonne; Zhou, Cathy; Szafer-Glusman, Edith; Ninomoto, Joi; Dean, James P; James, Danelle F; Ghia, Paolo; Tam, Constantine S
Link alla scheda completa:
Pubblicato in: